-639-5449 ClinicalTrials.gov Identifier: NCT01111825 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity Principal Investigator: Mihaela Cristea, MD Condition
Search Results
, Vanderbilt-Ingram Cancer Center • 800-811-8480 ClinicalTrials.gov Identifier: NCT00983268 A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Principal Investigator
F. Anthony Greco
Med 2004 ; 350 : 2335 – 2342 . 4. Sandler AB Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer . N Engl J Med 2006 ; 355 : 2542 – 2550 . 5. Moore MJ Goldstein D Hamm J . Erlotinib
Leora Horn
in Oncology (NCCN Guidelines) for NSCLC, many chemotherapy drugs are useful for treating patients with advanced-stage NSCLC. Among them are platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, docetaxel
Athanassios Argiris
-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head & neck cancer (LAHNC) (Abstr) . Proc Am Soc Clin Oncol 2003 ; 22 : A1997 . 8 Vermorken JB Remenar E Van Herpen C . Standard cisplatin/infusional 5
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel
Maurie Markman
: 4265 – 4269 . 16 Francis P Rowinsky E Schneider J . Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study . J Clin Oncol 1995 ; 13 : 2961 – 2967 . 17 Markman
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
doxorubicin (PLD) seems to significantly reduce the incidence of HSRs attributable to carboplatin compared with administering carboplatin as a single agent or in combination with paclitaxel. 31 , 32 The effect of PLD on reducing carboplatin-related infusion
Neelima Vidula, Leif W. Ellisen, and Aditya Bardia
III study compared veliparib with carboplatin and paclitaxel followed by maintenance veliparib versus chemotherapy in germline BRCA1/2 -mutant HER2-negative advanced breast cancer. 18 Median PFS improved from 12.6 to 14.5 months with the addition of
Presenters: Melinda L. Telli and William J. Gradishar
1mic disease. 3 Treatment with weekly paclitaxel for 12 cycles plus trastuzumab for 1 year led to a 7-year OS rate of 95%, with only 4 of 406 patients experiencing distant recurrences. The subsequent ATEMPT trial evaluated the newer agent ado
